Special issues in the management of infective endocarditis caused by gram-positive cocci

Infectious Disease Clinics of North America

Volumn 16, Issue 2, 2002, Pages 437-452

  Hoen, Bruno ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; EVERNIMICIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; METICILLIN; NETILMICIN; ORITAVANCIN; PENICILLIN G; RIFAMPICIN; STREPTOGRAMIN; STREPTOMYCIN; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN; ACETAMIDE DERIVATIVE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; VIRGINIAMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; BACTERIAL ENDOCARDITIS; CLINICAL TRIAL; ENTEROCOCCUS; GRAM POSITIVE COCCI; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTPATIENT; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS BOVIS; ANIMAL; CLASSIFICATION; DISEASE MANAGEMENT; DRUG EFFECT; DRUG RESISTANCE; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANIMAL; ANTIBIOTICS; ANTIBIOTICS, AMINOGLYCOSIDE; DISEASE MANAGEMENT; DRUG RESISTANCE; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE COCCI; HUMAN; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; VIRGINIAMYCIN; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS;

EID: 0036086783     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(01)00004-6     Document Type: Review

References (71)

1. The Gulstonian lectures on malignant endocarditis
2. Characteristics of infective endocarditis in France in 1991. A 1-year survey
3. Clinical and morphological characteristics in Streptococcus bovis endocarditis: A comparison with other causative microorganisms in 177 cases
4. Is the clinical spectrum and prognosis of native valve infective endocarditis in non-addicts changing?
5. Changing profile of infective endocarditis: Results of a one-year survey in France
6. Antibiotic susceptibility of streptococci and related genera causing endocarditis: Analysis of UK reference laboratory referrals, January 1996 to March 2000
7. Antibiotic treatment of streptococca, enterococcal, and staphylococcal endocarditis
8. Staphylococcal endocarditis - Recommendations for therapy
9. Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci, and other streptococci
10. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms
11. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility
12. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: A prospective multicenter study
13. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci
14. Glycopeptide tolerance in bacteria causing endocarditis
15. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis
16. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood
17. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States
18. Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis
19. Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and cefotaxime
20. Endocarditis due to Streptococcus mitis with highlevel resistance to penicillin and ceftriaxone
21. Abiotrophia elegans sp. nov., a possible pathogen in patients with culture-negative endocarditis
22. Antimicrobial susceptibility of Abiotrophia adiacens and Abiotrophia defectiva
23. Abiotrophia related endocarditis: Contribution of molecular biology
24. PCR for detection and identification of Abiotrophia spp
25. Vancomycin-resistant enterococci
26. Importance of the aminoglycoside dosing regimen in the penicillinnetilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis
27. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations
28. Teicoplanin alone or in combination with ceftriaxone, levofloxacin, and imipenem in the treatment of experimental endocarditis due to aminoglycoside-resistant Enterococcus faecalis
29. Efficacy of ampicillin (A) plus ceftriaxone (C) and gentamicin (G) in the treatment of Enterococcus faecalis experimental endocarditis in rabbits
30. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium
31. Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin-and glycopeptide-resistant isolate of Enterococcus faecium
32. Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactamresistant and highly glycopeptide-resistant isolate of Enterococcus faecium
33. Review of pneumococcal endocarditis in adults in the penicillin era
34. Streptococcus pneumoniae endocarditis in adults - A multicenter study in France in the era of penicillin resistance (1991-1998)
35. Austrian syndrome caused by highly penicillin-resistant Streptococcus pneumoniae
36. Infective endocarditis caused by highly penicillin-resistant Streptococcus pneumoniae: Successful treatment with cefuzonam, ampicillin and imipenem
37. Endocarditis caused by drug-resistant Streptococcus pneumoniae in a child
38. Infective endocarditis caused by Streptococcus pneumoniae with high-level resistance to penicillin and cephalosporin
39. Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae
40. Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae
41. Infective endocarditis caused by beta-hemolytic streptococci
42. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin
43. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis
44. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy
45. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial
46. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis
47. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis
48. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains
49. Teicoplanin therapy for Staphylococcus aureus septicaemia: Relationship between pre-dose serum concentrations and outcome
50. Treatment of endocarditis with teicoplanin: A retrospective analysis of 104 cases
51. Once-daily aminoglycosides in the treatment of gram-positive endocarditis
52. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis
53. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: Case report and review
54. Outpatient treatment of infective endocarditis
55. Outpatient intravenous antibiotic therapy for endocarditis
56. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics
57. Quinupristin/dalfopristin for treatment of MRSA endocarditis refractory to conventional therapy
58. Staphylococcus epidermidis endocarditis treated with RP 59500 (quinupristin/dalfopristin)
59. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy
60. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations
61. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination
62. Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid
63. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
64. Efficacy of linezolid in a staphylococcal endocarditis rabbit model
65. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis
66. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid
67. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
68. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis
69. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycinresistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
70. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis
71. In vivo activities of evernimicin (SCH 27899) against vancomycin-susceptible and vancomycin-resistant enterococci in experimental endocarditis